QuickView for Betamethasone (compound)

Summary
General Info

PubChem

PubChem Compound 3003

Name:	Betamethasone
PubChem Compound ID:	3003
Description:	A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)
Molecular formula:	C₂₂H₂₉FO₅
Molecular weight:	392.461 g/mol
Synonyms:	Betasolon; Betamamallet; Celestene; Betapredol; Flubenisolone; 9-Fluoro-16.beta.-methylprednisolone; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11.beta.,16.alpha.)-; Becort; Bebate; Celestone. show more » Betasolon; Betamamallet; Celestene; Betapredol; Flubenisolone; 9-Fluoro-16.beta.-methylprednisolone; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11.beta.,16.alpha.)-; Becort; Bebate; Celestone; Cidoten; 9.alpha.-Fluoro-16.beta.-methylprednisolone; Betacorlan; Betamethazone; Hormezon; Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17,21-trihydroxy-16.beta.-methyl-; Corticosterone, 1-dehydro-9-fluoro-17-hydroxy-16.beta.-methyl-; Desacort-Beta; .beta.-Methasone; Betnelan; Dexamethasone; Betacortril; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11.beta.,16.beta.)-; .beta.-Methasone alcohol; Methazon; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17, 21-trihydroxy-16-methyl-, (11.beta.,16.beta.)-; Rinderon; 378-44-9; Betsolan; SCH 4831; Valisone; Diproderm; NSC39470; 9-Fluoro-11.beta.,17, 21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione; Betamethasone; Prednisolone, 9-fluoro-16.beta.-methyl- show less «

DrugBank

Identification

Name:	Betamethasone
Name (isomeric):	DB00443
Drug Type:	small molecule
Description:	A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)
Brand:	Diprolene AF, Diprosone, Betamethasone Valerate, Flubenisolone, Betamethazone, Desacort-Beta, Uticort, Betametasone [DCIT], Betamethasonum [INN-Latin], Betasolon, Beta-Methasone, Valisone, Bebate, Betamethasone Cream, Alphatrex, Betadexamethasone, Rinderon A, Betamethasone Sodium Phosphate, Betatrex, Betafluorene, Betnelan, Betamethasone Dipropionate, Becort, Beta-Methasone Alcohol, Diproderm, Rinderon, Betamethasone Base, Betamamallet, Valnac, Betamethasone [Usan:Ban:Inn:Jan], Dermabet, Luxiq, Betsolan, Betapredol, Maxivate, Bedifos, Celestone, Cidoten, Celestene, Visubeta, Luxiqo, Betamethasone Alcohol, Beta-Val, Betacortril, Hormezon, Lotrisone, Methazon, Betacorlan, Betamethasone Valearate, Diprolene, Betametasona [INN-Spanish], Betaderm, Betamethasonvalerat Mikron, Celestone Syrup and Tablets
Brand name mixture:	Lotrisone(betamethasone + clotrimazole)
Category:	Anti-Asthmatic Agents, Anti-inflammatory Agents, Steroidal, Glucocorticoids, Immunosuppressive Agents, Corticosteroid, Anti-inflammatory Agents
CAS number:	378-44-9

Pharmacology

Indication:	<b>Topical use (cream, lotion and ointment):</b> for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses<br/><b>Topical use (foam):</b> relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp<br/><b>Systemic use:</b> for the treatment of edocrine disorders, rheumatic disorders, collagen diseases, dermatological diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, tuberculous meningitis and trichinosis.
Pharmacology:	Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, o... show more » Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections. show less «
Mechanism of Action:	Betamethasone is a glucocorticoid receptor agonist. This leads to changes in genetic expression once this complex binds to the GRE. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukot... show more » Betamethasone is a glucocorticoid receptor agonist. This leads to changes in genetic expression once this complex binds to the GRE. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin. show less «
Absorption:	Minimal if applied topically.
Protein binding:	64%
Biotransformation:	Hepatic
Half Life:	5.6 hours
Toxicity:	Symptoms of overdose include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Take with food to reduce irritation.

Drug interaction:

Trisalicylate-choline	The corticosteroid, betamethasone, may decrease the effect of the salicylate, trisalicylate-choline.
Warfarin	The corticosteroid, betamethasone, alters the anticoagulant effect of warfarin.
Butabarbital	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, betamethasone.
Amobarbital	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, betamethasone.
Ambenonium	The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, ambenonium.

Trisalicylate-choline	The corticosteroid, betamethasone, may decrease the effect of the salicylate, trisalicylate-choline.
Warfarin	The corticosteroid, betamethasone, alters the anticoagulant effect of warfarin.
Butabarbital	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, betamethasone.
Amobarbital	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, betamethasone.
Ambenonium	The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, ambenonium.
Acenocoumarol	The corticosteroid, betamethasone, alters the anticoagulant effect, acenocoumarol.
Fosphenytoin	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, betamethasone.
Salsalate	The corticosteroid, betamethasone, may decrease the effect of the salicylate, salsalate.
Quinidine barbiturate	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone.
Butethal	The barbiturate, butethal, may decrease the effect of the corticosteroid, betamethasone.
Phenobarbital	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, betamethasone.
Primidone	The barbiturate, primidone, may decrease the effect of the corticosteroid, betamethasone.
Edrophonium	The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, edrophonium.
Secobarbital	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, betamethasone.
Ethotoin	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, betamethasone.
Pyridostigmine	The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, pyridostigmine.
Mephenytoin	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, betamethasone.
Bismuth Subsalicylate	The corticosteroid, betamethasone, may decrease the effect of the salicylate, bismuth subsalicylate.
Magnesium salicylate	The corticosteroid, betamethasone, may decrease the effect of magnesium salicylate.
Talbutal	The barbiturate, talbutal, may decrease the effect of the corticosteroid, betamethasone.
Phenytoin	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, betamethasone.
Vecuronium	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Betamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
Dicumarol	The corticosteroid, betamethasone, alters the anticoagulant effect of dicumarol.
Trastuzumab	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Pentobarbital	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, betamethasone.
Anisindione	The corticosteroid, betamethasone, alters the anticoagulant effect of anisindione.
Methylphenobarbital	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, betamethasone.
Dihydroquinidine barbiturate	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone.
Acetylsalicylic acid	The corticosteroid, betamethasone, may decrease the effect of the salicylate, acetylsalicylic acid.
Heptabarbital	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, betamethasone.
Methohexital	The barbiturate, methohexital, may decrease the effect of the corticosteroid, betamethasone.
Tacrine	Tacrine and Betamethasone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
Aprobarbital	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, betamethasone.
Midodrine	Increased arterial pressure
Hexobarbital	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, betamethasone.
Salicylate-sodium	The corticosteroid, betamethasone, may decrease the effect of the salicylate, salicylate-sodium.
Butalbital	The barbiturate, butalbital, may decrease the effect of the corticosteroid, betamethasone.
Rifampin	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, betamethasone.

show less «

Targets

Glucocorticoid receptor

Enzymes

Cytochrome P450 3A4

Cytochrome P450 19A1

Transporters

Multidrug resistance protein 1